Phospho-EGFR (Tyr1092) Antibody
Description
Introduction to Phospho-EGFR (Tyr1092) Antibody
Phospho-EGFR (Tyr1092) Antibody is a specialized immunological reagent designed to recognize and bind specifically to the epidermal growth factor receptor (EGFR) protein only when it is phosphorylated at tyrosine residue 1092. This high specificity enables researchers to detect activated EGFR in various experimental contexts. The antibody detects endogenous levels of EGFR exclusively when this specific tyrosine residue is phosphorylated, making it an invaluable tool for studying EGFR signaling dynamics .
It is worth noting that there exists some nomenclature variation in the scientific literature regarding this phosphorylation site. Some researchers refer to this site as Tyr1068, which represents the same position after accounting for the removal of the signal peptide . This distinction is important when comparing research findings across different publications and commercial antibody products.
The production of these antibodies generally involves immunization with synthetic phosphopeptides derived from human EGFR containing the Tyr1092 phosphorylation site. Specifically, many manufacturers use peptides corresponding to amino acids 1061-1110 or similar regions surrounding the phosphorylation site .
For polyclonal antibodies, the production process typically involves:
-
Immunization of rabbits with the synthetic phosphopeptide
-
Collection of serum containing antibodies
-
Purification via antigen affinity chromatography using the immunizing phosphopeptide
Recombinant monoclonal antibodies follow a more sophisticated production pathway:
-
Isolation of antibody DNA sequences from immunoreactive rabbits
-
Cloning these sequences into expression vectors
-
Expression in systems such as HEK293F cells
-
Screening and selection of optimal clones
Functional Significance of EGFR Tyr1092 Phosphorylation
Understanding the biological significance of Tyr1092 phosphorylation is essential for appreciating the value of antibodies targeting this specific modification. EGFR belongs to the HER/ERbB family of proteins that includes three other receptor tyrosine kinases: ERbB2, ERbB3, and ERbB4 .
The phosphorylation of Tyr1092 occurs following EGFR dimerization, which is triggered by binding of cognate ligands such as Epidermal Growth Factor (EGF) and Transforming Growth Factor alpha (TGF-α) to the extracellular domain. This phosphorylation event creates a critical docking site for downstream signaling molecules .
Particularly significant is the fact that autophosphorylation at Tyr1092 recruits Signal Transducer and Activator of Transcription 3 (STAT3), a transcription factor implicated in cellular proliferation, survival, and oncogenesis . This specific interaction makes Tyr1092 phosphorylation a crucial event in EGFR-mediated signaling pathways relevant to cancer biology and therapeutic intervention strategies.
Western Blot Analysis
Western blotting represents one of the most common applications for Phospho-EGFR (Tyr1092) antibodies. For optimal results, these antibodies are typically used at dilutions ranging from 1:500 to 1:3000 . Key considerations for Western blot applications include:
-
Sample preparation: Cells are often treated with EGF to induce EGFR phosphorylation, as validated in experimental models using HeLa cells
-
Protein denaturation: Standard SDS-PAGE conditions are suitable for detection
-
Expected molecular weight: The phosphorylated EGFR is typically observed at 134-180 kDa
-
Control samples: Inclusion of untreated controls is essential to confirm specificity for the phosphorylated form
Immunohistochemistry and Immunofluorescence
For tissue and cellular localization studies, Phospho-EGFR (Tyr1092) antibodies are employed in both immunohistochemistry (IHC) and immunofluorescence (IF) applications. Typical working dilutions range from 1:50 to 1:200 . These techniques allow visualization of phosphorylated EGFR within cellular contexts, revealing both expression levels and subcellular localization patterns.
ELISA Applications
Enzyme-Linked Immunosorbent Assay (ELISA) represents a highly sensitive quantitative method for detecting phosphorylated EGFR in research samples. For this application, considerably higher dilutions are often employed, sometimes reaching 1:20000 . This high sensitivity makes ELISA particularly valuable for detecting low abundance phosphorylated EGFR in complex biological samples.
Flow Cytometry
For flow cytometry applications, dilutions typically range from 1:50 to 1:200 . This technique allows researchers to quantify phosphorylated EGFR at the single-cell level within heterogeneous populations, offering insights into cellular heterogeneity in EGFR activation states.
EGFR in Oncogenesis
Overexpression and aberrant activation of EGFR have been linked to numerous types of cancer, making it a critical target for both biological and small molecular therapeutics . Phospho-EGFR (Tyr1092) antibodies have been instrumental in studying these processes in various tumor types, including:
-
Head and neck cancer
-
Brain tumors
-
Bladder cancer
-
Breast cancer
-
Lung cancer
-
Endometrial cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Gastric cancer
The ability to specifically detect phosphorylated EGFR at Tyr1092 provides researchers with a precise tool to evaluate receptor activation status in these different cancer contexts, potentially correlating with disease progression and therapeutic response.
Therapeutic Development and Monitoring
Given the central role of EGFR in cancer progression, numerous therapeutics targeting this receptor have been developed. Phospho-EGFR (Tyr1092) antibodies serve as essential tools for:
-
Evaluating the efficacy of EGFR-targeted therapies in preclinical models
-
Monitoring treatment response in experimental systems
-
Identifying potential resistance mechanisms involving alterations in EGFR phosphorylation patterns
-
Developing companion diagnostics for patient stratification in precision medicine approaches
Advanced Imaging Techniques
The development of advanced imaging methodologies, including super-resolution microscopy and multiplexed imaging platforms, opens new possibilities for utilizing Phospho-EGFR (Tyr1092) antibodies in spatial analyses of receptor activation patterns within complex tissues and cellular microenvironments.
Single-Cell Analysis
Emerging single-cell technologies present opportunities to examine EGFR phosphorylation heterogeneity at unprecedented resolution. Phospho-EGFR (Tyr1092) antibodies compatible with single-cell protein analysis methods could reveal critical insights into cellular diversity in receptor activation states within tumors and other heterogeneous tissues.
Liquid Biopsy Applications
The potential adaptation of Phospho-EGFR (Tyr1092) detection methods to liquid biopsy formats represents an exciting frontier. Development of highly sensitive assays capable of detecting phosphorylated EGFR in circulating tumor cells or extracellular vesicles could provide minimally invasive approaches for monitoring treatment response and disease progression.
Product Specs
Target Background
- Amphiregulin, contained in non-small-cell lung carcinoma-derived exosomes, induces osteoclast differentiation through the activation of the EGFR pathway. PMID: 28600504
- Combining vorinostat with an EGFRTKI can reverse EGFRTKI resistance in NSCLC. PMID: 30365122
- The feasibility of utilizing the radiocobalt labeled antiEGFR affibody conjugate ZEGFR:2377 as an imaging agent has been explored. PMID: 30320363
- Among all transfection complexes, 454 lipopolyplexes modified with the bidentate PEG-GE11 agent exhibit the most efficient EGFR-dependent uptake, as well as luciferase and NIS gene expression into PMID: 28877405
- EGFR amplification was found to be higher in the OSCC group compared to the control group (P=0.018) and was associated with advanced clinical stage (P=0.013), regardless of age. Patients exhibiting EGFR overexpression had poorer survival rates, as did those with T3-T4 tumors and positive margins. EGFR overexpression negatively impacts disease progression. PMID: 29395668
- Clonal analysis reveals that the dominant JAK2 V617F-positive clone in Polycythemia Vera harbors the EGFR C329R substitution. This mutation may contribute to clonal expansion. PMID: 28550306
- Baseline Circulating tumor cell count could serve as a predictive biomarker for EGFR-mutated and ALK-rearranged non-small cell lung cancer, providing enhanced guidance and monitoring for patients undergoing molecular targeted therapies. PMID: 29582563
- High EGFR expression is linked to cystic fibrosis. PMID: 29351448
- These findings suggest a mechanism for EGFR inhibition to suppress respiratory syncytial virus by activating endogenous epithelial antiviral defenses PMID: 29411775
- This study identified the emergence of the T790M mutation within the EGFR cDNA in a subset of erlotinib-resistant PC9 cell models through Sanger sequencing and droplet digital PCR-based methods, demonstrating that the T790M mutation can arise de novo following erlotinib treatment. PMID: 29909007
- The present study demonstrated that miR145 regulates the EGFR/PI3K/AKT signaling pathway in patients with nonsmall cell lung cancer. PMID: 30226581
- Among NSCLC patients treated with EGFR-TKI, those with T790M mutations were found to frequently also exhibit 19 dels, compared to T790M-negative patients. Additionally, T790M-positive patients had a longer PFS. Therefore, screening these patients for T790M mutations may contribute to improved survival. PMID: 30150444
- High EGFR expression is associated with Breast Carcinoma. PMID: 30139236
- Results indicate that CAV-1 could promote anchorage-independent growth and anoikis resistance in detached SGC-7901 cells. This is associated with the activation of Src-dependent epidermal growth factor receptor-integrin beta signaling, as well as the phosphorylation of PI3K/Akt and MEK/ERK signaling pathways PMID: 30088837
- Our findings suggest that FOXK2 inhibits the malignant phenotype of clear-cell renal cell carcinoma and acts as a tumor suppressor, possibly through the inhibition of EGFR. PMID: 29368368
- EGFR mutation status in advanced non-small cell lung cancer (NSCLC) patients has changed significantly. PMID: 30454543
- Different Signaling Pathways in Regulating PD-L1 Expression in EGFR Mutated Lung Adenocarcinoma PMID: 30454551
- Internal tandem duplication of the kinase domain delineates a genetic subgroup of congenital mesoblastic nephroma, transcending histological subtypes PMID: 29915264
- The expression level of EGFR increased along with higher stages and pathologic grades of BTCC, and the notably increased expression of HER-2 was statistically associated with clinical stages and tumor recurrence. Furthermore, the expression level of HER-2 increased with higher clinical stage of BTCC. EGFR expression and HER-2 levels were positively associated in BTCC samples. PMID: 30296252
- Results demonstrate that GGA2 interacts with the EGFR cytoplasmic domain to stabilize its expression, reducing its lysosomal degradation. PMID: 29358589
- Combination therapy of apatinib with icotinib for primary acquired resistance to icotinib may be a viable option for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. However, physicians must remain cognizant of the side effects associated with this therapy. PMID: 29575765
- This report presents a rare case manifesting as multiple lung adenocarcinomas with four different EGFR gene mutations identified in three lung tumors. PMID: 29577613
- The study supports the involvement of EGFR, HER2, and HER3 in BCC aggressiveness and tumor differentiation towards distinct histological subtypes. PMID: 30173251
- The ratio of sFlt-1/sEGFR could serve as a novel candidate biochemical marker for monitoring the severity of preterm preeclampsia. sEndoglin and sEGFR might be implicated in the pathogenesis of small for gestational age in preterm preelampsia. PMID: 30177039
- The study confirmed the prognostic effect of EGFR and VEGFR2 for recurrent disease and survival rates in patients with epithelial ovarian cancer. PMID: 30066848
- The data suggest that diagnostic or therapeutic chest radiation may predispose patients with decreased stromal PTEN expression to secondary breast cancer, and that prophylactic EGFR inhibition may mitigate this risk. PMID: 30018330
- This research proposes a unique regulatory feature of PHLDA1, inhibiting the ErbB receptor oligomerization process and thereby controlling the activity of the receptor signaling network. PMID: 29233889
- The study observed the occurrence not only of the EGFR C797S mutation but also L792F/Y/H in three NSCLC clinical subjects exhibiting acquired resistance to osimertinib treatment. PMID: 28093244
- Data indicate that the expression level of epidermal growth factor-like domain 7 (EGFL7) and epidermal growth factor receptor (EGFR) in invasive growth hormone-producing pituitary adenomas (GHPA) is considerably higher than that of non-invasive GHPA. PMID: 29951953
- Concurrent mutations in genes such as CDKN2B or RB1 were associated with worse clinical outcome in lung adenocarcinoma patients with EGFR active mutations. PMID: 29343775
- The ER-alpha36/EGFR signaling loop promotes growth of hepatocellular carcinoma cells. PMID: 29481815
- High EGFR expression is linked to colorectal cancer. PMID: 30106444
- High EGFR expression is associated with gefitinib resistance in lung cancer. PMID: 30106446
- High EGFR expression is associated with tumor-node-metastasis in nonsmall cell lung cancer. PMID: 30106450
- Data suggest that Thr264 in TRPV3 is a key ERK1 phosphorylation site mediating EGFR-induced sensitization of TRPV3 to stimulate signaling pathways involved in regulating skin homeostasis. (TRPV3 = transient receptor potential cation channel subfamily V member-3; ERK1 = extracellular signal-regulated kinase-1; EGFR = epidermal growth factor receptor) PMID: 29084846
- The EGFR mutation frequency in Middle Eastern and African patients is higher than that observed in white populations but remains lower than the frequency reported in Asian populations. PMID: 30217176
- EGFR-containing exosomes derived from cancer cells could favor the development of a liver-like microenvironment, promoting liver-specific metastasis. PMID: 28393839
- The results reveal that the EGF-STAT3 signaling pathway promotes and maintains colorectal cancer (CRC) stemness. Furthermore, crosstalk between STAT3 and Wnt activates the Wnt/beta-catenin signaling pathway, which is also responsible for cancer stemness. Therefore, STAT3 is a potential therapeutic target for CRC treatment. PMID: 30068339
- This finding indicates that the T790M mutation is not only associated with EGFR-TKI resistance but may also play a functional role in the malignant progression of lung adenocarcinoma. PMID: 29887244
- LOX regulates EGFR cell surface retention to drive tumor progression. PMID: 28416796
- In a Han Chinese population, EGFR gene polymorphisms, rs730437 and rs1468727, and haplotype A-C-C were shown to be potential protective factors against the development of Alzheimer's Disease. PMID: 30026459
- EGFR proteins at different cellular locations in lung adenocarcinoma might influence the biology of cancer cells and serve as an independent indicator of a more favorable prognosis and treatment response. PMID: 29950164
- This report presents the crystal structure of EGFR T790M/C797S/V948R in complex with EAI045, a novel type of EGFR TKI that binds to EGFR reversibly and does not rely on Cys 797. PMID: 29802850
- Overexpression of miR-452-3p promoted cell proliferation and mobility while suppressing apoptosis. MiR-452-3p enhanced EGFR and phosphorylated AKT (pAKT) expression but inhibited p21 expression levels. MiR-452-3p promoted hepatocellular carcinoma (HCC) cell proliferation and mobility by directly targeting the CPEB3/EGFR axis. PMID: 29332449
- This study demonstrates that the D2A sequence of the UPAR induces cell growth through alphaVbeta3 integrin and EGFR. PMID: 29184982
- BRAF and EGFR inhibitors can synergize to enhance cytotoxic effects and diminish stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells. PMID: 29534162
- This study confirms a direct correlation between MSI1 and EGFR, potentially supporting the significant role of MSI1 in the activation of EGFR through NOTCH/WNT pathways in esophageal squamous cell carcinoma. PMID: 30202417
- Three lines of tyrosine kinase inhibitors (TKIs) therapy can extend survival in non-small cell lung cancer (NSCLC) patients. Elderly patients can benefit from TKI therapy. Patients with EGFR mutations can benefit from second-line or third-line TKI therapy. PMID: 29266865
- EGFR 19Del and L858R mutations are valuable biomarkers for predicting the clinical response to EGFR-TKIs. 19Del mutations may lead to a better clinical outcome. PMID: 29222872
- HMGA2-EGFR constitutively induced a higher level of phosphorylated STAT5B than EGFRvIII. PMID: 29193056
